CN104434877A - Poly methyl olefinic acid-containing macromolecule drug microcapsule - Google Patents

Poly methyl olefinic acid-containing macromolecule drug microcapsule Download PDF

Info

Publication number
CN104434877A
CN104434877A CN201310421967.2A CN201310421967A CN104434877A CN 104434877 A CN104434877 A CN 104434877A CN 201310421967 A CN201310421967 A CN 201310421967A CN 104434877 A CN104434877 A CN 104434877A
Authority
CN
China
Prior art keywords
acid
drug
polymer
polymethylacrylic acid
polymethylacrylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310421967.2A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Green Kht Science And Technology Ltd
Original Assignee
Chengdu Green Kht Science And Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Green Kht Science And Technology Ltd filed Critical Chengdu Green Kht Science And Technology Ltd
Priority to CN201310421967.2A priority Critical patent/CN104434877A/en
Publication of CN104434877A publication Critical patent/CN104434877A/en
Pending legal-status Critical Current

Links

Abstract

The present invention discloses a polymethacrylic acid-containing macromolecule drug microcapsule. The preparation method comprises: adopting an atom transfer radical polymerization method to polymerize methacrylic acid to obtain polymethacrylic acid; modifying the polymethacrylic acid with folic acid molecules; adopting a ring-opening polymerization method to polymerize glutamic acid stearyl ester carboxylic anhydride to obtain poly glutamic acid stearyl ester; grafting adriamycin on the poly glutamic acid stearyl ester; bonding the polymethacrylic acid and the poly glutamic acid through a click chemistry method to obtain a block copolymer; respectively dissolving the block polymer in tetrahydrofuran, transferring into a dialysis bag, carrying out dialysis with purified water, and filtering the dialyzed solution with a filtration membrane; and carrying out freeze-drying on the filtered solution to obtain the drug-loaded micelles, wherein the drug carrier micelles have a core-shell double-layer structure, the outer layer is the hydrophilic polymethacrylic acid, and the inner layer is the drug molecule wrapping layer. According to the present invention, the material has the following advantages that: the material belongs to the nanoparticles; the targeted drug delivery on the cancer cells and the pH-sensitive drug release in the cancer cells can be achieved; the drug loading is high; the stability is good; and with the targeting function, the toxic-side effect of the drug on the normal tissues and organs can be effectively reduced.

Description

A kind of polymer drug microcapsule containing poly-methyl olefin(e) acid
Technical field
The present invention relates to a kind of polymer drug microcapsule containing polymethylacrylic acid, particularly relate to a kind of preparation method with the block macromolecular material pharmaceutical carrier microcapsule of cancer cell targeting.Belong to polymer chemistry and technical field of polymer.
Background technology
Cancer has become the main disease of harm humans health, and one of important means of Therapeutic cancer is Drug therapy, but many cancer therapy drugs also exist and are insoluble in the defect such as water, poor stability.As camptothecine, paclitaxel, amycin, 5-fluorouracil etc. are all difficult to because of poor solubility be utilized well by organism, solve the crux that its water solubility problems is this kind of pharmaceutical preparation clinical practice.In addition, oncotherapy and its effect of diagnostic medicine are nonselective mostly, and some normal structure organs often have more distribution, and under therapeutic dose, normal tissue organ toxic and side effects is large.Therefore solve how solubilising slightly solubility cancer therapy drug and increase medicine stability, improve the selectivity of cancerous cell extremely urgent.Therefore, finding a kind of reliable target medicine carrier is the key solving above two problems.
What macromolecule micelle pharmaceutical carrier generally adopted is all linear polymeric micelle.The research work that Bae seminar carries out is the most noticeable, and it points out in delivered research paper, is linked on main polymer chain by Dox key with hydrazone key, and utilizes pH in cancerous cell microenvironment to be that faintly acid makes hydrazone bond fission, achieves the target spot release of Dox.And, one section of paper (Bae Y, Jang W-D, Nishiyama N, Fukushima S, Kataoka K. that Bae delivered on Molecular BioSystems magazine in 2005 mol BioSyst2005; 1 (3): 242-250.), first simultaneously by Fol and Dox respectively key link PEG and PASP(poly-aspartate) on, thus having targeted delivery and the target spot release multifunctionality of medicine concurrently, Flow cytometry experiments (FCM) shows that cell is not significantly increased containing the polymer micelle of Fol the intake of polymer micelle.Gong Shaoqin seminar has also been engaged in similar research.It is with poly caprolactone random copolymer is kernel, and PEG is shell, has prepared polymer nano micelle.Dox is connected with hydrazone key, and the PEG end group that utilized Fol to modify, prepare pH responsive type target drug-carrying micelle, test cellular uptake amount and cytotoxicity, prove that Dox discharges (Yang X, Grailer JJ, Pilla S fast due to the fracture of hydrazone key in acid condition, Steeber DA, Gong S. bioconjugate Chem2010; 21 (3): 496-504.).
Although linear polymer micelle is as the carrier of poorly water soluble drugs, demonstrate huge advantage and potential passing in medicine process, but still there is micelle poor stability, solubilizing effect is not obvious, drug release rate is low problem.The drug loading of current polymer micelle can only reach about 5% usually, obtain higher drug loading very difficult.Research finds, polymer connects medicine monomer by chemical bond, can reach higher drug loading.And linear block copolymers load capacity is often on the low side, if but cross multikey to connect its micellar structure of drug molecule unstable again.And star-type polymer can overcome this deficiency.
Shanghai Communications University Yan De high mountain (Liu J, Pang Y, Huang W, Huang X, Meng L, Zhu X, Zhou Y, Yan D. biomacromolecules2011; 12 (5): 1567-1577.) synthesize dendroid poly phosphate-polylactic-acid block copolymer and be applied to pharmaceutical carrier research, after parcel Dox, have obvious inhibitory action to HeLa cell.Another representative research is that Chinese University of Science and Technology Liu generation is brave, utilizes functionalization the polymaleic anhydride star-type polymer modified with Fol and Dox prepared by cyclodextrin, and key has connected the gadolinium element to magnetic resonance effect sensitivity simultaneously, finds in mouse experiment, polymer micelle has obvious reinforcement (Liu T, Li X, Qian Y in the gathering at liver, kidney position, Hu X, Liu S. biomaterials2012; 33 (8): 2521-2531.).
But because polymer architecture in star-type polymer is comparatively complicated, poor biocompatibility appears in prepared pharmaceutical carrier, drug encapsulation ability declines, the problems such as dendrimer surface drug macromolecule water-solubility reduction.In addition, dendrimer complex structure, synthesis cost is higher.These problems all limit the application of star-type polymer nano medicament carrying system.Therefore, no matter be property polymer or common star-type polymer pharmaceutical carrier, can not possess: target-oriented drug simultaneously, high drug carrying capacity, micellar structure is stablized, the pH sensitivity of target spot release, biocompatibility height these several plays the performance of most important effect to the clinical practice of polymer drug carrier system.
Summary of the invention
The object of the invention is to set up a kind of polymer drug microcapsule containing polymethylacrylic acid, this pharmaceutical carrier microcapsule has the following advantages: belong to nanoparticle; Medicine can be realized to pH sensitivity release in cancerous cell targeted delivery and cancerous cell; Drug loading is large; Good stability; Its target function can effectively reduce medicine normal tissue organ toxic and side effects.
This micelle is a kind of star block copolymer with hydrophilic and hydrophobic block; Can by amycin key connect with block polymer on; Macromolecular material has two hydrophilic segments, a hydrophobic segment: its hydrophilic section of macromolecular material is polymethylacrylic acid, is modified by folic acid.Hydrophobic section is polyglutamic acid, by hydrazone keyed jointing branch amycin; High molecular micellar structure has nucleocapsid double-decker, and skin is hydrophilic polymethylacrylic acid, and internal layer is drug molecule integument.
Described block polymer is the polymer in following structural formula:
The technology of preparing scheme of block copolymer microcapsule is as follows:
1) nitrine micromolecule initiator is prepared
2) synthesis of folic acid-NHS molecule
3) atom transfer radical polymerization of polymethylacrylic acid and modified with folic acid
4) synthesis of both arms alkynes end group polyglutamic acid octadecane ester
5) Dox molecule is connected with the hydrazone key of polyglutamic acid octadecane ester
6) synthesis of star block copolymer
7) capsule of nano is prepared
Polymer nanocomposite microcapsule is prepared by dialysis.Concrete grammar is: after one or both star polymers are dissolved in THF respectively, moves in bag filter, with 1000 mL pure water dialysis, refreshes the water periodically.After dialysis solution membrane filtration, lyophilization obtains copolymer carrier micelle.
By above technical scheme, tool of the present invention has the following advantages: the polymer drug microcapsule volume 1) containing polymethylacrylic acid is little, has nanoscale structures, can pass through various barrier in human body;
2) the polymer drug microcapsule critical micelle concentration containing polymethylacrylic acid is little, Stability Analysis of Structures;
3) the polymer drug microcapsule drug loading containing polymethylacrylic acid is large, and good biocompatibility;
4) the polymer drug microcapsule containing polymethylacrylic acid has Targeting delivery pharmic function, can effectively reduce medicine normal tissue organ toxic and side effects.
Accompanying drawing explanation
Fig. 1 is this high molecular structural representation;
Fig. 2 is the schematic diagram of this high molecule microcapsule;
Fig. 3 is the AFM scintigram of this high molecule microcapsule.
Detailed description of the invention
For making enforcement object of the present invention, technical scheme and advantage more clear, below in conjunction with the drawings and specific embodiments of the present invention, the present invention is described in detail:
As shown in Figure 1, be the chemical constitution schematic diagram of the polymer drug microcapsule containing polymethylacrylic acid.This macromolecule is AB 22. type block macromolecular, have two hydrophilic section, and 3. a hydrophobic section formed.Key on each segment has connected different molecular structures:
Folic acid micromolecule 1. key is connected in polymethylacrylic acid molecule segment and 2. goes up, and is 2. prepared by Transfer Radical Polymerization;
3. the five-membered ring utilizing 1,3-Dipolar Cycloaddition to obtain and polyglutamic acid carry out coupling;
Utilize hydrazone key by segment 3. with Doxorubicin molecules 4. key link up.
As shown in Figure 2, a kind of polymer drug microcapsule containing polymethylacrylic acid is by this AB 2assorted arm star block macromolecular assembling is formed.Its structure is respectively by 1. folic acid micromolecule; 2. polymethyl acid molecule; 3. polyglutamic acid; 4. the composition such as Doxorubicin molecules.Macromolecule is in aqueous by hydrophobic interaction, and can self assembly be spherical micellar structure, high molecular microcapsule structure has nucleocapsid double-decker:
Skin be hydrophilic polymethylacrylic acid 2.;
Internal layer be polyglutamic acid 3., be drug molecule integument, internal layer can make drug molecule be wrapped in ball interior, thus realizes drug carrier function.
Figure 3 shows that AB 2assorted arm star block copolymer is the AFM scanogram of spherical microcapsule structure that formed of self assembly in aqueous.Prove that macromolecule forms globular micelle structure homogeneous, good dispersion, does not reunite in aqueous, is conducive to realizing the delivery to drug molecule and release function.
Provide embodiment below to be specifically described the present invention; but it is worthy of note that following examples are only used to further illustrate the present invention; can not be interpreted as limiting the scope of the invention, some nonessential improvement that the person skilled in the art in this field makes the present invention according to the invention described above content and adjustment still belong to protection scope of the present invention.
Embodiment 1:
1. nitrine micromolecule initiator is prepared
Step one: 2-chloroethoxyethanol 5mL is dissolved in 25mL butanone, adds 4.5g NaN in solution 3, 2.5gBu 4nI, 10mg bicyclohexane also-hexaoxacyclooctadecane-6-6, mixture is heated to boiling, stir 24 hours.Filtered by mixture, precipitation acetone carries out cleaning down.The mixed solution obtained is the crude product of product, after mixed solution is concentrated, 90 oc carries out distillation and obtains pure substance.The 2-nitrine ethoxy ethanol obtained 1h NMR (CDCl 3): 3.70 (t, 2 H, C h 2oH), 3.65 (t, 2h, HOCH 2c h 2o), 3.56 (t, 2H, N 3cH 2c h 2o), 3.37 (t, 2H, C h 2n 3), and 2.56 (s, 1H, OH).
Step 2: by a kind of for step obtained 2-nitrine ethoxy ethanol 2g, alpha-chloro acyl chlorides 5.09g is dissolved in 30mL dichloromethane, reaction system is transferred in ice territory, is slowly added in reaction vessel by 6.8g dicyclohexylcarbodiimide, and stir.0.4g dimethylamino naphthyridine is dissolved in dichloromethane and instilled in reaction vessel in 10 minutes.Whole reaction system is 0 oreact 1 hour under C condition, then at room temperature react 24 hours.The cyclohexyl urea be precipitated out in course of reaction is filtered, and washs with dichloromethane.Extract with sodium bicarbonate solution (5%), then carry out drying with anhydrous magnesium sulfate.After reduced vacuum drying, be separated with silica gel chromatographic column, finally obtain product 2-chloro nitrine Ethoxyethane. 1H NMR (CDCl 3): 4.30 (t, 2H, CH 2OCO), 3.73 (t, 2H, COOCH 2C H 2O), 3.67 (t, 2H, N 3CH 2C H 2O), 3.35 (t, 2H, C H 2N 3), and 1.92 (s, 6H, (CH 3) 2C)。
2. the synthesis of folic acid-NHS molecule
By 1.0g folic acid and 0. 495g N, N-dicyclohexylcarbodiimide (DCC) and 0. 463g N-hydroxysuccinimide (NHS) are dissolved in 20mL DMSO, at N 2the lower room temperature reaction 24h of protection, cross and filter byproduct of reaction N, N-dicyclohexyl urine (DCU), utilizes silica gel chromatographic column to be separated, can obtain folic acid-NHS molecule.
3. the atom transfer radical polymerization of polymethylacrylic acid and modified with folic acid
By the 2-nitrine ethyoxyl bromo acid 12mg obtained in step 2, add methanol, bipyridyl and cuprous bromide with the 5.4g methacrylic acid ratio be dissolved in simultaneously in 2:1:1 in 25mL DMSO.By bleeding-ventilate for three times-thaw cycles carries out tube sealing to polymerization pipe.Be polymerized after 24 hours, with methanol, polymer be precipitated out, filter, dry stand-by.Polymethylacrylic acid obtained by 2g is dissolved in 20mL dichloromethane, adds 2.8mL ethylenediamine, the terminal groups of polymethylacrylic acid is modified, obtain the polymer of end group band primary amine.The polymethylacrylic acid that 2g end group is modified is warming up to 50 oc reacts 6h.Reactant liquor is loaded bag filter (MWCO=3500) after having reacted, the 2 days free folic acid of removing afterwards of dialysing in deionized water, changes water every day 3 times.Dialysis solution ether sedimentation, vacuum drying obtains product.
4. the synthesis of both arms alkynes end group polyglutamic acid octadecane ester
Step one: 16.8g 3,5-methyl dihydroxy benzoate and 26.2g propargyl bromide are dissolved in 300mL acetone, add 15.1g sodium carbonate in the solution, 0.1g bicyclohexane also-hexaoxacyclooctadecane-6-6.Reaction solution is carried out be heated to backflow, react 24 hours.By sedimentation and filtration after reaction terminates, filtrate carries out concentrating under reduced pressure, in methanol, carry out recrystallization, obtains product 3,5-diacetylene p-methoxybenzoic acid methyl ester. 1H NMR in CDCl 3, δ(ppm): 2.55 (2H, CCH), 3.91(3H, CH 3 O), 4.73 (4H, CH 2 CCH), 6.82 (1H, aromatic), 7.29 (2H, aromatic)。
Step 2: 6.25g3,5-diacetylene p-methoxybenzoic acid methyl ester is dissolved in 30mL methanol, 73.9g ethylenediamine is dissolved in 120mL ethylenediamine, and 0 oslowly be added dropwise in reaction vessel under C condition, the process that drips needs 1 hours, and reaction 96 hours under room temperature again after being added dropwise to complete.Be less than 40 orevolve in the water-bath of C to steam and remove unnecessary solvent, utilizing the mixed solution of benzene/methanol (9/1 v/v) to carry out recrystallization to mixed solution, in vacuum drying oven, drying 24 hours, obtains product N-amine ethyl 3,5-diethyl alkynyloxy group aniline. 1H NMR in CDCl 3, δ(ppm): 1.61 (2H,
CH 2 NH 2), 2.55 (2H, CCH), 2.95 (2H, CH 2NH 2), 3.49 (2H, CONH CH 2), 4.73 (4H, CH 2CCH), 6.68 (1H, CO NH), 6.76 (1H, aromatic), 7.05 (2H, aromatic)。
Step 3: by the product N-amine ethyl 3 obtained in 0.16g step 2,5-diethyl alkynyloxy group aniline is as initiator, utilize ring-opening polymerisation mode polymer poly glutamic acid octadecane ester carboxylic acid anhydrides 5.19g, monomer and initiator are added in polymerization pipe, and add dry DMF 15mL, react 24 hours under room temperature.Polymer absolute ether precipitates, dry 24 hours of vacuum drying oven.Obtain product both arms alkynes end group polyglutamic acid octadecane ester.
5. Doxorubicin molecules is connected with the hydrazone key of polyglutamic acid octadecane ester
The both arms alkynes end group polyglutamic acid octadecane ester obtained in 5.8mL hydrazine and 2.43g above-mentioned steps is dissolved in the dry DMF of 25mL, reaction system is heated to 40 oc, reacts 1 hour.Thick product absolute ether is precipitated, and by sedimentation and filtration, dry 24 hours of vacuum drying oven, obtains amido both arms alkynes end group polyglutamic acid octadecane ester.This product 5g and 0.34g amycin monomer are dissolved in DMSO, reaction system is heated to 30 oc, react 48 hours, the reaction mixture absolute methanol obtained precipitates, and by sedimentation and filtration, dry 24 hours of vacuum drying oven.The polyglutamic acid octadecane ester of obtained Doxorubicin molecules grafting.
6. AB 2the synthesis of assorted arm star block copolymer
The polymethylacrylic acid modify 3.8g end group and the polyglutamic acid octadecane ester of 7.8g Doxorubicin molecules grafting are dissolved in 20mL dry DMF, and add 6.93mg PMDETA.Reaction system is carried out-ventilation-thaw cycles of bleeding for three times, add rapidly cuprous bromide 5.47mg.Reaction is 35 oreact 24 hours under C condition.React the mixed solution obtained and cross silicagel column to remove unnecessary mantoquita and other impurity.The concentrated later absolute methanol of solution precipitates, and finally obtains AB 2assorted arm star block copolymer.
7. the preparation of polymer nanocomposite microcapsule
Polymer nanocomposite microcapsule is prepared by dialysis.Concrete grammar is: after one or both star polymers are dissolved in THF respectively, moves in bag filter, with 1000 mL pure water dialysis, refreshes the water periodically.After dialysis solution membrane filtration, lyophilization obtains copolymer drug-loading microcapsule.
Finally it should be noted that, above embodiment is only in order to illustrate technical scheme of the present invention and unrestricted, although with reference to preferred embodiment to invention has been detailed description, those of ordinary skill in the art should understand, can a point technical scheme for invention be modified or be replaced on an equal basis, and not departing from the spirit and scope of technical solution of the present invention, it all should be encompassed in the middle of right of the present invention.

Claims (8)

1., containing a polymer drug microcapsule for polymethylacrylic acid, its architectural feature is: described macromolecular material is the AB by two hydrophilic polymethylacrylic acid segments and the coupling of a hydrophobic polyglutamic acid octadecane ester segment 2type copolymer.
2. the method preparing the polymer drug microcapsule containing polymethylacrylic acid according to claim 1 is carried out as follows:
1) for causing the synthesis of the nitrine micromolecule initiator of methacrylic acid monomer;
2) utilize folic acid micromolecule to carry out NHS activation, prepare folic acid-NHS molecule;
3) utilize the nitrine micromolecule initiator prepared by step 1), cause methacrylic acid micromolecule and carry out atom transfer radical polymerization, obtain polymethylacrylic acid, utilize folic acid-NHS molecular modification polymethylacrylic acid simultaneously;
4) synthesis of both arms alkynes end group polyglutamic acid octadecane ester;
5) utilize Doxorubicin molecules to carry out grafting to polyglutamic acid octadecane ester, this reaction utilizes hydrazone key to connect;
6) click chemistry Reactive Synthesis star block copolymer is utilized;
7) polymer nano micelle is prepared by dialysis.
3. the preparation method of a kind of polymer drug microcapsule containing polymethylacrylic acid according to claim 2, is characterized in that solvent that in said method, synthesized by step 1), nitrine micromolecule initiator uses is any one in acetone, butanone, dioxane, acetonitrile.
4. the preparation method of a kind of polymer drug microcapsule containing polymethylacrylic acid according to claim 2, is further characterized in that the polymerization single polymerization monomer that in said method, step 4) uses is glutamic acid octadecane ester carboxylic acid anhydrides.
5. the preparation method of a kind of polymer drug microcapsule containing polymethylacrylic acid according to claim 2, is further characterized in that the polymer coupling reaction that in said method, step 6) is carried out must adopt Huisgen 1,3-Dipolar Cycloaddition.
6. the preparation method of a kind of polymer drug microcapsule containing polymethylacrylic acid according to claim 2, is further characterized in that in said method and needs to adopt following micromolecule initiator:
1) 2-chloro nitrine Ethoxyethane
2) N-amine ethyl 3,5-diethyl alkynyloxy group aniline.
7. a kind of polymer drug microcapsule containing polymethylacrylic acid according to claim 2, is further characterized in that: this macromolecular material is the star block copolymer formed by coupling by the polymethylacrylic acid segment of modified with folic acid and the polyglutamic acid of amycin grafting.
8. a kind of polymer drug microcapsule containing polymethylacrylic acid according to claim 2, be further characterized in that: described macromolecule micelle has nucleocapsid double-decker, skin is hydrophilic polymethylacrylic acid, and internal layer is drug molecule integument.
CN201310421967.2A 2013-09-16 2013-09-16 Poly methyl olefinic acid-containing macromolecule drug microcapsule Pending CN104434877A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310421967.2A CN104434877A (en) 2013-09-16 2013-09-16 Poly methyl olefinic acid-containing macromolecule drug microcapsule

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310421967.2A CN104434877A (en) 2013-09-16 2013-09-16 Poly methyl olefinic acid-containing macromolecule drug microcapsule

Publications (1)

Publication Number Publication Date
CN104434877A true CN104434877A (en) 2015-03-25

Family

ID=52882145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310421967.2A Pending CN104434877A (en) 2013-09-16 2013-09-16 Poly methyl olefinic acid-containing macromolecule drug microcapsule

Country Status (1)

Country Link
CN (1) CN104434877A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0769900A (en) * 1993-08-31 1995-03-14 Yasuhisa Sakurai Water-soluble anticancer agent
CN1662259A (en) * 2002-06-19 2005-08-31 日本化药株式会社 Process for producing block copolymer/drug composite
CN101972480A (en) * 2010-01-19 2011-02-16 南京泛太化工医药研究所 Docetaxel polymeric micelle medicine composition taking amino acid as stabilizing agent
CN103059312A (en) * 2012-12-12 2013-04-24 中科院广州化学有限公司 Amphipathic ternary molecular brush polymer constructed multichannel nanocapsule

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0769900A (en) * 1993-08-31 1995-03-14 Yasuhisa Sakurai Water-soluble anticancer agent
CN1662259A (en) * 2002-06-19 2005-08-31 日本化药株式会社 Process for producing block copolymer/drug composite
CN101972480A (en) * 2010-01-19 2011-02-16 南京泛太化工医药研究所 Docetaxel polymeric micelle medicine composition taking amino acid as stabilizing agent
CN103059312A (en) * 2012-12-12 2013-04-24 中科院广州化学有限公司 Amphipathic ternary molecular brush polymer constructed multichannel nanocapsule

Similar Documents

Publication Publication Date Title
CN104415010A (en) Preparation method of antitumor micelle containing adriamycin
CN104415013A (en) Novel antitumor polymer drug containing adriamycin
CN104415339A (en) Self-assembled targeted nanometer drug carrier micelles
CN104415342A (en) Self-assembled drug carrier microcapsule system containing polypyrrolidone
CN104415012A (en) Preparation method of medical polymer drug
CN105169405A (en) Preparation method of adriamycin polymer drug
CN104415344A (en) Polymer drug microcapsule containing polyacrylic acid
CN104414999A (en) Anti-tumor targeted nanometer drug-loaded microcapsule preparation method
CN104415343A (en) Self-assembled drug carrier microcapsule system containing polyacrylic acid
CN104415003A (en) Polymer nano drug microcapsule containing polypyrrolidone
CN103977417A (en) Preparation method of amphiphilic drug-loaded nanoparticles
CN103977418A (en) Preparation method of doxorubicin-containing anti-tumor micelles
CN104434794A (en) Novel adriamycin tumor cell inhibiting micelle preparation method
CN104414996A (en) Nano self-assembly drug carrier microcapsule system
CN104415341A (en) Preparation method of tumor cell micro-environmentally responsive targeted drug micelle
CN104415002A (en) Preparation method for antineoplastic high-molecular microcapsule
CN104415011A (en) Preparation method of cellular microenvironment pH-sensitive micelle
CN104415007A (en) Preparation method of tumor cell micro-environmentally responsive nano-micelle
CN104337767A (en) Method for preparing pH sensitive drug carrier micelle
CN104415004A (en) Preparation method of biocompatible polymer antitumor drug
CN104337794A (en) Intelligent amphiphilic targeting drug carrier system
CN104415005A (en) Novel anti-cancer polymer drug
CN103990140A (en) Nanometer self-assembly drug carrier system
CN103990139A (en) Preparation method for medicinal high-molecule carrier
CN104434877A (en) Poly methyl olefinic acid-containing macromolecule drug microcapsule

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150325

WD01 Invention patent application deemed withdrawn after publication